Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18948622 | SYSTEM AND METHOD FOR GENERATING A BODY MODIFICATION PROTOCOL | November 2024 | October 2025 | Abandon | 11 | 2 | 0 | No | No |
| 18544307 | MEDICAL SUPPORT DEVICE, OPERATION METHOD OF MEDICAL SUPPORT DEVICE, OPERATION PROGRAM OF MEDICAL SUPPORT DEVICE, LEARNING DEVICE, AND LEARNING METHOD | December 2023 | February 2026 | Abandon | 26 | 2 | 0 | No | No |
| 18483632 | PHYSIOLOGICAL CONDITION INFORMATION FOR REMOTE HEALTHCARE DETERMINATION | October 2023 | January 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18228640 | SYSTEM AND METHOD FOR AN ENHANCED PATIENT USER INTERFACE DISPLAYING REAL-TIME MEASUREMENT INFORMATION DURING A TELEMEDICINE SESSION | July 2023 | October 2025 | Allow | 27 | 4 | 0 | Yes | No |
| 18220937 | MEDICAL DEVICE MANAGEMENT SYSTEM, MANAGEMENT SERVER, MEDICAL DEVICE, AND MEDICAL DEVICE MANAGEMENT METHOD | July 2023 | October 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18345140 | SYSTEMS AND METHODS FOR USING AI/ML AND FOR CARDIAC AND PULMONARY TREATMENT VIA AN ELECTROMECHANICAL MACHINE RELATED TO UROLOGIC DISORDERS AND ANTECEDENTS AND SEQUELAE OF CERTAIN UROLOGIC SURGERIES | June 2023 | October 2025 | Allow | 27 | 4 | 0 | Yes | No |
| 18344371 | MACHINE LEARNING FOR OPTIMIZING OVARIAN STIMULATION | June 2023 | November 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18186950 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND INFORMATION PROCESSING PROGRAM | March 2023 | November 2025 | Abandon | 32 | 1 | 0 | Yes | No |
| 18167812 | METHOD AND PROCESS FOR PREDICTING AND ANALYZING PATIENT COHORT RESPONSE, PROGRESSION, AND SURVIVAL | February 2023 | March 2026 | Abandon | 37 | 2 | 0 | No | No |
| 18164132 | HEALTHCARE DATA EXCHANGE | February 2023 | May 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18092041 | ADAPTABLE OPERATION RANGE FOR A SURGICAL DEVICE | December 2022 | July 2025 | Allow | 31 | 1 | 0 | No | No |
| 17969051 | OUTCOMES AND PERFORMANCE MONITORING | October 2022 | April 2025 | Abandon | 29 | 3 | 0 | No | No |
| 17960406 | CLINICAL RISK MODEL | October 2022 | March 2026 | Abandon | 41 | 3 | 0 | Yes | No |
| 17861672 | MULTI-MODEL MEMBER OUTREACH SYSTEM | July 2022 | September 2025 | Abandon | 39 | 4 | 0 | Yes | No |
| 17832444 | PATIENT AUTHENTICATION AND REMOTE MONITORING FOR PULSED ELECTROMAGNETIC FIELD SYSTEMS | June 2022 | April 2025 | Abandon | 34 | 2 | 0 | Yes | No |
| 17747873 | SYSTEM AND METHOD FOR REMOTE PROVISION OF HEALTHCARE | May 2022 | March 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17541067 | SYSTEMS AND METHODS FOR DETERMINING ALTERNATIVE PAYMENTS FOR PHARMACEUTICAL THERAPIES AND DRUGS | December 2021 | May 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17538613 | DRIVE-THROUGH TREATMENT SYSTEM AND METHOD | November 2021 | July 2025 | Abandon | 44 | 3 | 0 | Yes | Yes |
| 17516942 | METHOD AND LOCAL AND REGIONAL CLOUD INFRASTRUCTURE SYSTEM FOR PRESSURE ELASTOGRAPHY MEASUREMENT DEVICES | November 2021 | January 2026 | Abandon | 51 | 4 | 0 | No | No |
| 17486171 | REHABILITATION ASSISTANCE SYSTEM, REHABILITATION ASSISTANCE METHOD, AND PROGRAM | September 2021 | November 2024 | Abandon | 38 | 2 | 0 | Yes | No |
| 17463707 | CLINICAL TRIALS MATCHING AND VISUALIZATION IN A CLINICAL GUIDELINE VIEW | September 2021 | September 2025 | Abandon | 48 | 4 | 0 | Yes | No |
| 17397864 | SCIENTIFIC AND TECHNICAL SYSTEMS AND METHODS FOR PROVIDING HAIR HEALTH DIAGNOSIS, TREATMENT, AND STYLING RECOMMENDATIONS | August 2021 | August 2023 | Abandon | 24 | 6 | 0 | Yes | No |
| 17420814 | MACHINE LEARNING TECHNIQUES FOR DETERMINING THERAPEUTIC AGENT DOSAGES | July 2021 | February 2025 | Abandon | 44 | 2 | 0 | Yes | No |
| 17352720 | MEDICAL INFORMATION PROCESSING APPARATUS, MEDICAL INFORMATION PROCESSING METHOD, AND STORAGE MEDIUM | June 2021 | December 2025 | Abandon | 54 | 4 | 0 | No | No |
| 17416330 | HEALTH RISK INFORMATION MANAGEMENT DEVICE, HEALTH RISK INFORMATION MANAGEMENT METHOD, AND PROGRAM | June 2021 | March 2025 | Abandon | 45 | 3 | 0 | Yes | No |
| 17328276 | METHODS AND SYSTEMS FOR REDUCING A RISK OF SPREAD OF AN ILLNESS IN A BUILDING | May 2021 | March 2025 | Abandon | 46 | 3 | 1 | Yes | No |
| 17207582 | CLINICAL CONCEPT IDENTIFICATION, EXTRACTION, AND PREDICTION SYSTEM AND RELATED METHODS | March 2021 | July 2025 | Allow | 52 | 6 | 0 | Yes | No |
| 17154200 | HEALTHCARE APPLICATION INSIGHT VELOCITY AID | January 2021 | January 2025 | Abandon | 48 | 4 | 0 | Yes | No |
| 17254942 | METHOD AND SYSTEM FOR PERSONALIZED HYPERTENSION TREATMENT | December 2020 | August 2025 | Abandon | 56 | 4 | 0 | Yes | No |
| 17110965 | PREDICTIVE DATA ANALYSIS TECHNIQUES FOR OPTIMAL TRAVERSAL OF INFECTION NETWORKS | December 2020 | October 2024 | Allow | 46 | 4 | 0 | Yes | No |
| 17096763 | JOINT STATE ESTIMATION PREDICTION THAT EVALUATES DIFFERENCES IN PREDICTED VS. CORRESPONDING RECEIVED DATA | November 2020 | February 2026 | Allow | 60 | 8 | 0 | Yes | No |
| 17072114 | SYSTEMS AND METHODS FOR PREDICTING RELATIVE PATIENT HAZARDS USING PHARMACEUTICAL ADHERENCE PREDICTIVE MODELS | October 2020 | July 2024 | Allow | 45 | 3 | 0 | Yes | No |
| 17064864 | SYSTEMS AND METHODS FOR PROVIDING HEALTH INFORMATION | October 2020 | July 2025 | Abandon | 57 | 4 | 0 | Yes | Yes |
| 17062526 | CLOUD ANALYTICS PACKAGES | October 2020 | October 2025 | Allow | 60 | 5 | 0 | Yes | No |
| 17034049 | PREDICTIVE DATA ANALYSIS TECHNIQUES FOR GENERATING OPTIMIZED DRUG DELIVERY ARRANGEMENTS | September 2020 | November 2024 | Abandon | 50 | 4 | 0 | Yes | No |
| 17008702 | ADAPTABLE REINFORCEMENT LEARNING | September 2020 | November 2024 | Abandon | 50 | 4 | 0 | Yes | No |
| 16998417 | Method And Apparatus For Planning A Procedure | August 2020 | January 2025 | Abandon | 53 | 8 | 0 | Yes | No |
| 16141732 | DYNAMIC PROMPTING FOR DIAGNOSIS SUSPECTING | September 2018 | July 2025 | Abandon | 60 | 10 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HRANEK, KAREN AMANDA.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HRANEK, KAREN AMANDA works in Art Unit 3684 and has examined 22 patent applications in our dataset. With an allowance rate of 22.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 50 months.
Examiner HRANEK, KAREN AMANDA's allowance rate of 22.7% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HRANEK, KAREN AMANDA receive 4.36 office actions before reaching final disposition. This places the examiner in the 98% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by HRANEK, KAREN AMANDA is 50 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +26.3% benefit to allowance rate for applications examined by HRANEK, KAREN AMANDA. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 6.3% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 4.3% of cases where such amendments are filed. This entry rate is in the 5% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 20% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 2% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.